These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Case report: severe thrombocytopenia].
    Author: Sakka SG, Schürmann A, Knüttgen D, Wappler F.
    Journal: Anasthesiol Intensivmed Notfallmed Schmerzther; 2009 Apr; 44(4):242-5. PubMed ID: 19367527.
    Abstract:
    In this case report, we describe the course of a chronic hemodialysis patient who has been treated for 7 days with linezolid for pneumonia caused by a methicillin-resistant staphylococcus aureus and who developed severe thrombocytopenia which was reversible after having stopped the treatment. Since there is an increasing evidence that linezolid induces severe thrombocytopenia, especially in patients requiring hemodialysis, indication for treatment with linezolid should be made with caution and monitoring of blood count in short-term intervals should be performed in critically ill patients. Linezolid is a representative of a new antibiotic class, i.e. an oxazolidinone, which inhibits the bacterial protein synthesis at the ribosom. Such agents do not have any relation to common anti-infectives and act nearly exclusively against Gram-positive bacteria and mycobacteria. In clinical practice, linezolid is most widely used for treatment of Gram-positive infections, mainly caused by methicillin-resistant Staphylococcus aureus (MRSA). The major adverse effects of linezolid are diarrhoea, nausea, and headache. Furthermore, abnormalities in blood count, i.e. leukocytopenia, thrombocytopenia and anaemia, have been reported.
    [Abstract] [Full Text] [Related] [New Search]